东阳光药港股第2日跌6%创新低 去年期内利润降98%

Core Viewpoint - Dongyangguang Pharmaceutical (东阳光药) experienced a significant decline in its stock price on its second trading day after its Hong Kong listing, indicating market volatility and investor concerns regarding its financial performance [1][2] Group 1: Stock Performance - On the second trading day, Dongyangguang Pharmaceutical closed at HKD 56.25, down 6.09%, with a lowest price of HKD 54.00, marking a new low [1] - On its first trading day, the stock closed at HKD 59.90, up 4.17%, reaching a peak of HKD 62.30, which represented an increase of 8.35% [2] Group 2: Financial Performance - The company reported a significant decline in revenue for 2024, with a year-on-year decrease of 37% [2] - Operating profit for 2024 fell by 78.4%, while net profit saw a drastic decline of 97.55% [2] - Revenue figures for 2022, 2023, and 2024 were reported as CNY 38.14 billion, CNY 63.86 billion, and CNY 40.19 billion respectively [2] - Gross profit for the same years was CNY 29.22 billion, CNY 50.77 billion, and CNY 30.59 billion [2] - Operating profit for 2022, 2023, and 2024 were CNY -7.93 billion, CNY 17.66 billion, and CNY 3.81 billion respectively [2] - Net profit figures for the same years were CNY -14.16 billion, CNY 10.14 billion, and CNY 248 million [2] Group 3: Listing Details - Dongyangguang Pharmaceutical's listing on the Hong Kong Stock Exchange is notable as it is the first case of H-share absorption merger privatization and introduction listing [1]